IDH wild-type WHO grade II diffuse low-grade gliomas. A heterogeneous family with different outcomes. Systematic review and meta-analysis.
Diffuse glioma
IDH wild-type
Isocitrate dehydrogenase
Low-grade glioma
Journal
Neurosurgical review
ISSN: 1437-2320
Titre abrégé: Neurosurg Rev
Pays: Germany
ID NLM: 7908181
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
22
03
2018
accepted:
14
06
2018
revised:
22
05
2018
pubmed:
27
6
2018
medline:
21
10
2020
entrez:
27
6
2018
Statut:
ppublish
Résumé
WHO grade II diffuse low-grade gliomas (DLGGs) were recently divided into sub-groups on the basis of their molecular profiles. IDH wild-type (IDH-wt) tumors seem to be associated with unfavorable prognoses due to biological similarities to glioblastomas. The authors performed a systematic review and meta-analysis of literature examining epidemiology, clinical characteristics, management, and the outcome of IDH-wt grade II DLGGs. According to PRISMA guidelines, a comprehensive review of studies published from January 2009 to October 2017 was carried out. The authors identified series that examined the prevalence rate, clinical and radiological characteristics, treatment, and outcome of IDH-wt DLGGs. Variables influencing outcomes were analyzed using a random-effects meta-analysis model. Finally, a meta-regression analysis was performed to examine the impact of therapeutic strategies on the effect-size. Twenty-two studies were included in this systematic review. The IDH-wt prevalence rate was 22.9% (95% CI 18.4-27.4%). The hazard ratio for this molecular subgroup in the DLGGs population was 3.46 (95% CI 2.24-5.36; p < 0.001), and the heterogeneity was significant (I
Identifiants
pubmed: 29943141
doi: 10.1007/s10143-018-0996-3
pii: 10.1007/s10143-018-0996-3
doi:
Substances chimiques
Isocitrate Dehydrogenase
EC 1.1.1.41
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
383-395Références
N Engl J Med. 2016 Apr 7;374(14):1344-55
pubmed: 27050206
Nat Rev Neurol. 2009 Dec;5(12):646-7
pubmed: 19953115
Neuro Oncol. 2017 Oct 1;19(10):1327-1337
pubmed: 28575485
PLoS One. 2015 Jun 26;10(6):e0130872
pubmed: 26115094
J Neurooncol. 2015 Jun;123(2):317-8
pubmed: 25917059
J Neurooncol. 2015 Sep;124(3):493-500
pubmed: 26243269
Oncol Rep. 2012 Nov;28(5):1639-44
pubmed: 22922798
Acta Neuropathol. 2015 Sep;130(3):407-17
pubmed: 26087904
Eur J Cancer. 1992;28A(8-9):1328-30
pubmed: 1515244
Glia. 2011 Aug;59(8):1181-9
pubmed: 21192095
Lancet Neurol. 2009 Sep;8(9):810-8
pubmed: 19665931
Acta Neurochir (Wien). 2010 Jan;152(1):19-26
pubmed: 19603136
Neuro Oncol. 2018 Jan 10;20(1):103-112
pubmed: 29016833
J Neurol Neurosurg Psychiatry. 2005 Jun;76(6):845-51
pubmed: 15897509
Epilepsia. 2014 Sep;55(9):1438-43
pubmed: 24903073
Neurosurgery. 2018 Jun 1;82(6):808-814
pubmed: 28945860
J Neurooncol. 2017 Nov;135(2):273-284
pubmed: 28884377
J Neurooncol. 2017 Dec;135(3):535-543
pubmed: 28836106
J Clin Oncol. 2013 Jan 20;31(3):337-43
pubmed: 23071247
World Neurosurg. 2016 Jul;91:548-559.e1
pubmed: 27004759
World Neurosurg. 2015 Jul;84(1):154-62
pubmed: 25779854
J Clin Oncol. 2002 Apr 15;20(8):2076-84
pubmed: 11956268
J Neurosurg. 2009 Apr;110(4):696-708
pubmed: 19133753
Lancet Oncol. 2016 Nov;17(11):1521-1532
pubmed: 27686946
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Science. 2008 Sep 26;321(5897):1807-12
pubmed: 18772396
J Neurooncol. 2017 May;133(1):37-45
pubmed: 28434111
Radiother Oncol. 2015 Sep;116(3):381-7
pubmed: 26328938
Oncotarget. 2015 Oct 6;6(30):30232-8
pubmed: 26338964
Oncotarget. 2015 Oct 6;6(30):30295-305
pubmed: 26210286
J Neurooncol. 2015 Jan;121(1):185-93
pubmed: 25261925
J Neurosurg. 2018 Apr 20;:1-10
pubmed: 29676695
Neuro Oncol. 2017 Feb 1;19(2):242-251
pubmed: 27571885
Rev Neurol (Paris). 2011 Oct;167(10):683-90
pubmed: 21889777
Neurology. 2010 Oct 26;75(17):1560-6
pubmed: 20975057
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Neurology. 2002 Sep 24;59(6):947-9
pubmed: 12297589
PLoS One. 2012;7(3):e32764
pubmed: 22427879
Neurology. 2012 Aug 28;79(9):883-9
pubmed: 22843268
Am J Pathol. 2009 Apr;174(4):1149-53
pubmed: 19246647
Cancer Sci. 2012 Mar;103(3):587-92
pubmed: 22136423
Mol Diagn Ther. 2014 Feb;18(1):45-53
pubmed: 23934769
J Neurosurg. 2012 Dec;117(6):1039-52
pubmed: 23039150
Clin Cancer Res. 2009 Oct 1;15(19):6002-7
pubmed: 19755387
Neurosurg Rev. 2008 Jul;31(3):263-9
pubmed: 18299912
Acta Neurochir (Wien). 2013 Jun;155(6):951-7
pubmed: 23447053
Sci Rep. 2016 Aug 30;6:32286
pubmed: 27574036
J Clin Oncol. 2012 Jul 10;30(20):2559-65
pubmed: 22529254
Neuro Oncol. 2014 Aug;16(8):1100-9
pubmed: 24847087
J Neurosurg. 2011 Nov;115(5):948-65
pubmed: 22043865
Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):497-504
pubmed: 25680596
Ann Neurol. 2003 Apr;53(4):524-8
pubmed: 12666121
CNS Oncol. 2015;4(4):247-56
pubmed: 26095141
J Neurooncol. 2016 Feb;126(3):499-507
pubmed: 26586262
Int J Oncol. 2012 Oct;41(4):1325-36
pubmed: 22825915
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Acta Neuropathol. 2015 Apr;129(4):585-96
pubmed: 25701198
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Phys Ther. 2009 Sep;89(9):873-80
pubmed: 19723669
Clin Cancer Res. 2010 Mar 1;16(5):1597-604
pubmed: 20160062
J Neurosurg. 2004 May;100(5):891-922
pubmed: 15137609
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
J Neurooncol. 2012 Aug;109(1):15-22
pubmed: 22528790
Cancer. 2012 Jan 15;118(2):452-60
pubmed: 21717448
Acta Neurochir (Wien). 1992;118(1-2):40-52
pubmed: 1414529
Acta Neuropathol. 2015 Jan;129(1):133-46
pubmed: 25427834
Acta Neuropathol. 2010 Dec;120(6):719-29
pubmed: 21080178
Clin Neurol Neurosurg. 2015 Nov;138:37-44
pubmed: 26276726
J Neurosurg. 2012 Feb;116(2):365-72
pubmed: 21999317
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120